# KRRO-110

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/krro-110
Canonical HTML page: https://getbiobrief.com/entity/krro-110

## Recent coverage (1 stories)

### Korro Bio Secures $85M in Oversubscribed Round to Advance RNA Editing Pipeline
2026-03-09 12:49:46 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Korro Bio has announced an oversubscribed $85 million private placement to accelerate its proprietary RNA editing platform and clinical development. The funding provides a significant runway for the company's lead program, KRRO-110, targeting Alpha-1 Antitrypsin Deficiency.
Full story: https://getbiobrief.com/story/korro-bio-85-million-private-placement-rna-editing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.